Journal profile · OPHTHALMOLOGY
Ophthalmology and Therapy
ISSN 2193-8245 · eISSN 2193-6528 · SPRINGER INTERNATIONAL PUBLISHING AG · ENGLAND · 6 issues per year
Ophthalmology and Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.15; fully open access; APC about USD 7,675; median 55 days to acceptance (99 articles, last 24 months); 214 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Ophthalmology and Therapy is published by SPRINGER INTERNATIONAL PUBLISHING AG and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Retinal Diseases and Treatments, Ophthalmology and Visual Impairment Studies and Glaucoma and retinal disorders, together about 36.7% of its articles. Its main subfields are Ophthalmology and Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)
Aims and ScopeOphthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques.The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.Rapid PublicationThe journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies.Open Access All articles published by Ophthalmology and Therapy are open access.Personal ServiceThe journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform with the journal’s submission guidelines. This supports the publication of ethically sound and transparent research.Digital Features and Plain Language SummariesOphthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompa
From the journal's Aims & Scope
Research area (LetPub): OPHTHALMOLOGY
Editorial board by country: 7 in mainland China (about 4%); most named United States 31, Italy 27, United Kingdom 23, India 14, Spain 10 (186 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Retinal Diseases and TreatmentsMedicine15.1%
- Ophthalmology and Visual Impairment StudiesMedicine11.9%
- Glaucoma and retinal disordersMedicine9.8%
- Corneal surgery and disordersMedicine9.3%
- Ocular Surface and Contact LensMedicine7.5%
- Retinal and Macular SurgeryMedicine6.6%
- Intraocular Surgery and LensesMedicine5.8%
- Ocular Diseases and Behçet’s SyndromeMedicine5.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Ophthalmology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Ophthalmology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Ophthalmology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.15LetPub ·
- Impact factor (publisher) 2025
- 4.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 4Publisher website ·
- CiteScore 2026-06
- 6.5LetPub ·
- SJR 2026-06
- 1.37LetPub ·
- SNIP 2026-06
- 1.61LetPub ·
- h-index
- 63OpenAlex ·
- i10-index
- 569OpenAlex ·
- 2-year mean citedness
- 4.04OpenAlex ·
- Self-citation rate
- 7.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 201LetPub ·
- Downloads per year (publisher) 2025
- 1,200,000Publisher website ·
Articles by year OpenAlex count · 1,483 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 202 | 202 | 88 |
| 2025 | 214 | 214 | 805 |
| 2024 | 213 | 213 | 1,650 |
| 2023 | 220 | 220 | 3,245 |
| 2022 | 191 | 191 | 2,917 |
| 2021 | 122 | 122 | 2,129 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
55 daysMedian, submission to acceptance · P25–P75 42 days – 73 days
- Acceptance to online
- median 22 days (99 articles)
- Submission to online
- median 81 days
- Sample
- 99 articles with submission and acceptance dates (460 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Acceptance to publication
- 28 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 5,950 / USD 7,675 / GBP 5,120 | Yes | CC BY-NC | |
| OpenAlex | USD 7,400 / EUR 5,750 / GBP 4,900 | — | — | |
| LetPub | EUR 5,500 / USD 6,850 / GBP 4,700 | Yes | — | |
| Publisher website | GBP 5,120 / EUR 5,950 / USD 7,675 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteAuthorship, License & copyright, Open access
- Authorship
Open access publishing; fees, funding and licences information on Open access publishing page Model summary
Open access publishing To find out more about publishing your work Open Access in Ophthalmology and Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·- License & copyright
Open access publishing; fees, funding and licences information on Open access publishing page Model summary
Open access publishing To find out more about publishing your work Open Access in Ophthalmology and Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·- Open access Open access publishing
Open access publishing; fees, funding and licences information on Open access publishing page Model summary
To find out more about publishing your work Open Access in Ophthalmology and Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SPRINGER INTERNATIONAL PUBLISHING AG
- Country or region
- ENGLAND
- Language
- English
- Frequency
- 6 issues per year
- ISSN
- 2193-8245
- Electronic ISSN
- 2193-6528
- Latest issue on the website
- Volume 15, Issue 10 (October 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Ophthalmology and Therapy
What CAS zone is Ophthalmology and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Ophthalmology and Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Ophthalmology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Ophthalmology and Therapy?
The latest impact factor listed by LetPub is 4.15; CiteScore 6.5, h-index 63.
How long does peer review take at Ophthalmology and Therapy?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 55 days (interquartile range 42–73 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Ophthalmology and Therapy based?
Of the 186 board members whose country the journal's board page names, 7 (about 4%) are in mainland China; the countries named most often are United States (31), Italy (27) and United Kingdom (23). Counted from the institutions listed on the board page; for reference only.
Which databases index Ophthalmology and Therapy?
According to LetPub and DOAJ records, Ophthalmology and Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase and Current Contents; that list has not been checked against each database.
Is Ophthalmology and Therapy open access, and what is the APC?
Ophthalmology and Therapy is a fully open-access journal. APC about USD 7,675.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .